Dianthus Therapeutics develops experimental drugs for severe autoimmune diseases, led by the antibody claseprubart. It last closed at $84.55 on Nov 20, down 0.33% on the day. The next earnings report for DNTH is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, DNTH reported EPS of -$0.81. Over its last 8 reports the stock moved an average of 4.8% the session after earnings. Over the last 12 months DNTH insiders bought $0 of stock on the open market and sold $75.1M, according to SEC Form 4 filings.
AI Auto Pilots
Is DNTH in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold DNTH.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on DNTHStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
DNTH · as of the Nov 20 close · updated each morning
Moving sideways
The stock is 1% below its 20 day and 2% below its 50 day average. It is 4% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 47). The nearest support is the Pivot at $84.25, and the nearest resistance the 20 day average at $85.42.
Short trendNeutral
Long trendBullish
MomentumImproving
StretchNormal
VolatilityNormal, 5.4%/day
Key levels
$117.8852 week high+39.4%
$96.28100 day average+13.9%
$91.24Swing high (Oct 2)+7.9%
$87.81200 day average+3.9%
$86.3750 day average+2.2%
$85.97Pivot R1+1.7%
$85.4220 day average+1.0%
$84.55Last close
$84.25Pivot−0.4%
$83.84Swing low (Nov 12)−0.8%
$82.83Pivot S1−2.0%
$35.8452 week low−57.6%
Indicators
RSI (14)
47.06
Middle of its range
Neutral
MACD
0.45
Above its signal line
Bullish
Stochastic
30.6
Middle of its range
Neutral
ADX (14)
23.6
Weak trend
Williams %R
-68.7
Oversold below −80, overbought above −20
Neutral
CCI (20)
-21.1
Oversold below −100, overbought above 100
Neutral
Rate of change
−1.7%
Change over 10 sessions
Bearish
ATR (14)
$4.54
Typical daily range, 5.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend
Short trendBearish
Long trendBullish
MomentumFading
StretchNormal
VolatilityLow, 11.6%/day
Key levels
$117.8852 week high+39.4%
$96.28100 day average+13.9%
$91.24Swing high (Oct 2)+7.9%
$87.81200 day average+3.9%
$86.3750 day average+2.2%
$85.97Pivot R1+1.7%
$85.4220 day average+1.0%
$84.55Last close
$84.25Pivot−0.4%
$83.84Swing low (Nov 12)−0.8%
$82.83Pivot S1−2.0%
$35.8452 week low−57.6%
Indicators
RSI (14)
47.29
Middle of its range
Neutral
MACD
-0.11
Below its signal line
Bearish
Stochastic
37.2
Middle of its range
Neutral
ADX (14)
28.6
Trending down
Williams %R
-68.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
-57.6
Oversold below −100, overbought above 100
Neutral
Rate of change
−20.4%
Change over 10 sessions
Bearish
ATR (14)
$9.82
Typical daily range, 11.6% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for DNTH
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how DNTH did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow DNTH usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for DNTHHow many large options trades hit DNTH, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in DNTH in the last 90 days.
From SEC Form 4 filings by DNTH's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DNTH is in one of them and how their past DNTH trades turned out.
Dianthus Therapeutics is a biotechnology company based in New York that develops experimental drugs for people with severe autoimmune diseases. Its lead candidate, claseprubart, is an antibody that blocks the active form of the C1s protein, and it is designed to be injected under the skin at home. Its second candidate, DNTH212, is a fusion protein that targets two immune pathways involved in autoimmune disease. Both candidates are still in clinical trials and are not yet approved for sale.